Orrick has advised San Francisco-based synthetic biology company Twist Bioscience (NASDAQ: TWST) on its $78.8 million follow-on offering of 3.750 million shares of common stock at $21 per share. In addition, Twist has granted the underwriters a 30-day option to purchase up to 562,500 additional shares of common stock.
The offering is expected to close on or about May 13, 2019, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers for the proposed offering. Robert W. Baird & Co. Incorporated is acting as lead manager.
Last year, Orrick advised Twist on its initial public offering on the Nasdaq Global Select Market. The Orrick team advising Twist on its follow-on offering includes Andy Thorpe, John Bautista, Pete Lamb and Melissa Frayer.